EXPO logo

EXPONENT INC

EXPONASDAQ
๐Ÿ† #1565 by market capEarnings Oct 28US Equity
$66.53โ–ผ $1.77 (โˆ’2.66%)
Live
1hโ–ผ 0.6%
24hโ–ผ 2.7%
7dโ–ผ 0.5%
14dโ–ฒ 1.2%
30dโ–ฒ 4.5%
1yโ–ผ 6.1%
๐ŸฆMarket Cap
$3.23B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+7.8%
Slowing
๐Ÿ“ŠGross Margin
91.4%
High
๐Ÿ’ตFCF Margin
20.3%
Strong
โš–๏ธP/S Ratio
5.4x
Fair
Otter Score
46
Weak

Trading Snapshot

Day Range
$66.10 โ€“ $67.42
52-Week Range
$51.91 โ€“ $81.95
Volume
$6.25B
Avg Volume
$6.30B
Shares Outstanding
48.5M
Next Earnings
Sep 18, 2026

Fundamentals Snapshot

Annual Revenue
$582M
Last Q Revenue
$172M
P/E Ratio
29.9
P/S Ratio
5.4x
EPS (TTM)
$2.14
Dividend Yield
1.90%

Why Investors Own EXPO

  • โœ“High-growth profile โ€” revenue up +10.2% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 31% gross margin and 5% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$582Mโ–ฒ +10.2% YoY
Gross Margin (TTM)
30.7%โ–ฒ +3.2% YoY
Operating Income (TTM)
$143Mโ–ฒ +10.2% YoY
Free Cash Flow (TTM)
$30Mโ–ฒ +10.2% YoY

About EXPONENT INC

Exponent, Inc. functions as a global leader in scientific and engineering consulting, operating through its subsidiaries. The firm's activities are divided into two principal segments: Engineering and Other Scientific, and Environmental and Health. The Engineering and Other Scientific division offers a broad spectrum of services encompassing biomechanics, biomedical sciences, structural analysis, civil engineering, construction advisory, data analytics, electrical and computer science, human factors, materials and corrosion science, mechanical engineering, polymer chemistry, thermal dynamics, and vehicle system engineering. Concurrently, the Environmental and Health segment specializes in areas such as chemical regulatory compliance, food safety, ecological and biological studies, earth and environmental sciences, and various health-related scientific fields. With expertise spanning approximately 90 technical disciplines, Exponent is dedicated to addressing complex and pressing issues for its stakeholders. Its client base is diverse, covering industries like chemicals, construction, consumer products, energy, food and beverage, government, life sciences, insurance, manufacturing, technology, heavy industrial equipment, and transportation. The company, originally established in 1967 as The Failure Group, Inc., rebranded as Exponent, Inc. in 1998, and its headquarters are located in Menlo Park, California.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
46/100

Analyst Ratings

โ“˜
Consensus
Buy
10 analysts
Strong Buy3
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

Yahooยท1d ago

H&MV Engineering valued at โ‚ฌ1.4 billion in new funding transaction

H&MV Engineering, a global provider of specialist high-voltage engineering and critical power infrastructure services, today announced the signing of a transaction to establish a continuation vehicle of approximately โ‚ฌ750 million, led by existing investor Exponent. The transaction extends Exponent's investment in H&MV and brings in Apollo S3, Pantheon and SQ Capital as investors to support the company's next phase of international growth.

Yahooยท4d ago

Exponent (EXPO) Q2 2026 Earnings Call Transcript

Revenue grew 12% to $148.9 million as AI user research and infrastructure demand accelerated.

Yahooยท9d ago

Wall Street Analysts Predict a 25.65% Upside in Exponent (EXPO): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 25.7% in Exponent (EXPO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

๐Ÿš€
Benzingaยท11d ago

UBS Maintains Neutral on Exponent, Lowers Price Target to $72

UBS analyst Joshua Chan maintains Exponent (NASDAQ:EXPO) with a Neutral and lowers the price target from $75 to $72.

๐Ÿ›ฐ๏ธ
Benzingaยท12d ago

JP Morgan Maintains Overweight on Exponent, Raises Price Target to $90

JP Morgan analyst Tomohiko Sano maintains Exponent (NASDAQ:EXPO) with a Overweight and raises the price target from $80 to $90.

Yahooยท12d ago

Exponent, Inc. Q2 2026 Earnings Call Summary

Moby summary of Exponent, Inc.'s Q2 2026 earnings call